Evolutec Group has launched a 300-patient Phase IIb trial of rEV131 in allergic rhinitis. The multi-dose, double-blind trial is being undertaken by Allied Research International in Toronto, Canada.
In particular, the study will determine the duration of action of rEV131, which is being administered as a nasal spray. The trial will be conducted using Allied's Environmental Exposure Chamber in which patients will be exposed to high levels of ragweed pollen for periods in excess of 12 hours. The primary endpoint of the trial is the sum of symptom scores after seven days of twice-daily dosing.